152 related articles for article (PubMed ID: 29703541)
1. Massive Hemoptysis after the First Administration of Pembrolizumab in a Strongly Positive, Centrally Located NSCLC.
Artal-Cortés A; Felices-Lobera P; Márquez-Medina D
J Thorac Oncol; 2018 May; 13(5):e76-e77. PubMed ID: 29703541
[No Abstract] [Full Text] [Related]
2. Early fatal hemoptysis after first-dose, first-line pembrolizumab in a central lung cancer: did tumor shrinkage matter?
Facchinetti F; Majori M; Sabato M; Gnetti L; Tiseo M
Immunotherapy; 2019 Feb; 11(3):161-166. PubMed ID: 30730279
[TBL] [Abstract][Full Text] [Related]
3. Fatal Airway Inflammation Induced by Pembrolizumab in a Patient With NSCLC.
Ogawa T; Miyata J; Maehara J; Inoue T; Betsuyaku T
J Thorac Oncol; 2019 Jan; 14(1):e9-e10. PubMed ID: 30579555
[No Abstract] [Full Text] [Related]
4. Fatal encephalopathy after pembrolizumab treatment for advanced non-small cell lung carcinoma.
Freitas C; Sampaio L; Fernandes G
J Neurooncol; 2019 Nov; 145(2):399-402. PubMed ID: 31506753
[No Abstract] [Full Text] [Related]
5. Vogt-Koyanagi-Harada Syndrome Induced by Pembrolizumab in a Patient with Non-Small Cell Lung Cancer.
Tamura T; Akimoto E; Matsumoto C; Mori S; Nishi T; Kudo K; Kuyama S
J Thorac Oncol; 2018 Oct; 13(10):1606-1607. PubMed ID: 29730378
[No Abstract] [Full Text] [Related]
6. Bevacizumab for non-small-cell lung cancer.
Oxnard GR
N Engl J Med; 2007 Mar; 356(13):1373; author reply 1374-5. PubMed ID: 17396305
[No Abstract] [Full Text] [Related]
7. Pembrolizumab for the treatment of PD-L1 positive advanced or metastatic non-small cell lung cancer.
Dang TO; Ogunniyi A; Barbee MS; Drilon A
Expert Rev Anticancer Ther; 2016; 16(1):13-20. PubMed ID: 26588948
[TBL] [Abstract][Full Text] [Related]
8. FDA Approval Summary: Pembrolizumab for the Treatment of Patients With Metastatic Non-Small Cell Lung Cancer Whose Tumors Express Programmed Death-Ligand 1.
Sul J; Blumenthal GM; Jiang X; He K; Keegan P; Pazdur R
Oncologist; 2016 May; 21(5):643-50. PubMed ID: 27026676
[TBL] [Abstract][Full Text] [Related]
9. Pembrolizumab (Keytruda) for first-line treatment of metastatic NSCLC.
Med Lett Drugs Ther; 2017 Jan; 59(1513):22-23. PubMed ID: 28118650
[No Abstract] [Full Text] [Related]
10. Endoscopic central airway recanalization to enable first line pembrolizumab treatment in a PD-L1 strongly positive non-small cell lung cancer: a case report.
Fiorelli A; Perrotta F; Mollica M; Santini M; Vitiello F; Gilli M; Calabrese C; Bianco A
J Cardiothorac Surg; 2019 Mar; 14(1):50. PubMed ID: 30832704
[TBL] [Abstract][Full Text] [Related]
11. A case of severe hemoptysis after stereotactic body radiotherapy for peripherally located stage I non-small cell lung cancer.
Kimura K; Tomita N; Shimizu A; Sato Y; Makita C; Kodaira T
Jpn J Radiol; 2015 Jun; 33(6):370-4. PubMed ID: 25900415
[TBL] [Abstract][Full Text] [Related]
12. Pembrolizumab Outperforms Docetaxel for NSCLC.
Leslie M
Cancer Discov; 2016 Mar; 6(3):223. PubMed ID: 26811324
[No Abstract] [Full Text] [Related]
13. Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial.
Brahmer JR; Rodríguez-Abreu D; Robinson AG; Hui R; Csőszi T; Fülöp A; Gottfried M; Peled N; Tafreshi A; Cuffe S; O'Brien M; Rao S; Hotta K; Zhang J; Lubiniecki GM; Deitz AC; Rangwala R; Reck M
Lancet Oncol; 2017 Dec; 18(12):1600-1609. PubMed ID: 29129441
[TBL] [Abstract][Full Text] [Related]
14. Use of denosumab in a patient with non-small-cell lung cancer and severe renal function impairment.
Govaerts E; Vansteenkiste J
J Thorac Oncol; 2013 Jun; 8(6):e52-3. PubMed ID: 23676561
[No Abstract] [Full Text] [Related]
15. Histologic Transformation in a Patient with Lung Cancer Treated with Chemotherapy and Pembrolizumab.
Hsu CL; Chen KY; Kuo SW; Chang YL
J Thorac Oncol; 2017 Jun; 12(6):e75-e76. PubMed ID: 28532567
[No Abstract] [Full Text] [Related]
16. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.
Reck M; Rodríguez-Abreu D; Robinson AG; Hui R; Csőszi T; Fülöp A; Gottfried M; Peled N; Tafreshi A; Cuffe S; O'Brien M; Rao S; Hotta K; Leiby MA; Lubiniecki GM; Shentu Y; Rangwala R; Brahmer JR;
N Engl J Med; 2016 Nov; 375(19):1823-1833. PubMed ID: 27718847
[TBL] [Abstract][Full Text] [Related]
17. Successful treatment by pembrolizumab in a patient with end-stage renal disease with advanced non-small cell lung cancer and high PD-L1 expression.
Ishizuka S; Sakata S; Yoshida C; Takaki A; Saeki S; Nakamura K; Fujii K
Respir Investig; 2018 Jul; 56(4):361-364. PubMed ID: 29764752
[TBL] [Abstract][Full Text] [Related]
18. Diabetic Ketoacidosis as an Immune-related Adverse Event from Pembrolizumab in Non-Small Cell Lung Cancer.
Leonardi GC; Oxnard GR; Haas A; Lang JP; Williams JS; Awad MM
J Immunother; 2017; 40(6):249-251. PubMed ID: 28557813
[TBL] [Abstract][Full Text] [Related]
19. Follicular psoriasis induced by pembrolizumab in a patient with advanced non-small-cell lung cancer.
Scarfì F; Lacava R; Patrizi A; Tartari F; Ravaioli GM; Veronesi G; Lambertini M; Dika E
Int J Dermatol; 2019 Aug; 58(8):e151-e152. PubMed ID: 30964199
[No Abstract] [Full Text] [Related]
20. Complete Atrioventricular Block Associated with Pembrolizumab-induced Acute Myocarditis: The Need for Close Cardiac Monitoring.
Katsume Y; Isawa T; Toi Y; Fukuda R; Kondo Y; Sugawara S; Ootomo T
Intern Med; 2018 Nov; 57(21):3157-3162. PubMed ID: 29877257
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]